®2®3 PLAINSBORO, N.J.and BAGSVÆRD, Denmark, Jan. 5, 2026 /PRNewswire/ -- Wegovy pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine in a pill for the first time. This advancement opens new possibilities for the more than 100 million Americans living with obesity. Wegovy pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-rel ...

Key Points Viking Therapeutics has important catalysts on the horizon. Zoetis looks well-positioned to overcome recent challenges. 10 stocks we like better than Viking Therapeutics › One great way to earn above-average market returns is to identify stocks that aren't performing well -- even as broader equities are moving higher -- but could eventually rebound. There are plenty of candidates to pick from as the stock market closes out another solid year. Two beaten-down stocks worth considering for ...

NEW TAIPEI CITY, Dec. 24, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity medications. Amid growing demand for such treatments, significant advancements in drug development are increasingly focused on long-term sustainability and safety to meet the needs of individuals struggling with weight maintenance.Eli Lilly and Co (NYSE:LLY) on Thursday shared topline results from the ATTAIN-MAINTAIN Ph ...

Core Viewpoint - BioAge Labs is a small biotech company that has seen a significant increase in its stock price due to clinical progress in weight management, but it remains unattractive for long-term investors due to high risks associated with its clinical stage and intense competition in the market [1][7]. Group 1: Company Overview - BioAge Labs' shares have increased by 122% year to date, currently priced at $12.88 with a market cap of $462 million [5][6]. - The company is developing a single candidate, BGE-102, which is still in phase 1 clinical trials, making it a high-risk investment [4][3]. Group 2: Clinical Development - BioAge Labs has only one candidate in clinical trials, which is in phase 1, indicating a lack of advanced clinical data compared to competitors [4][3]. - Positive interim results for BGE-102 have been reported, but the overall risk remains high due to the early stage of development [4]. Group 3: Market Competition - The weight management market is expected to grow rapidly, attracting many major pharmaceutical companies and smaller firms, increasing competition for BioAge Labs [6][7]. - Success for BioAge Labs will depend on the safety and efficacy of BGE-102, but uncertainty remains regarding its ability to compete effectively in the anti-obesity market [7]. Group 4: Investment Alternatives - Other biotech companies, such as Viking Therapeutics, are further along in clinical trials, having completed phase 2 and currently in phase 3 for their lead candidate, VK2735, presenting a less risky investment option [8]. - Investors may face the risk of BioAge Labs shares becoming worthless in the future, suggesting a cautious approach towards investment in this company [9].

Core Insights - Pfizer is making significant moves in the weight management market, which is expected to grow rapidly in the next decade, potentially rewarding leading companies handsomely [1][2] - The acquisition of Metsera for $7 billion, with potential milestone payments bringing the total to $10 billion, positions Pfizer as a strong contender in the weight management space [3][4] - Pfizer's CEO, Albert Bourla, expressed confidence in the company's ability to succeed in the obesity market, drawing parallels to past successes with drugs like Lipitor and COVID products [7] Company Developments - Pfizer's acquisition of Metsera indicates its commitment to entering the weight management market, especially after competing with Novo Nordisk for the deal [3][4] - Metsera's leading candidate, MET-097i, has shown promising results in clinical trials, indicating potential for substantial weight loss and good tolerability [6] - Pfizer plans to launch its first anti-obesity drug by the end of 2028, although Eli Lilly currently holds a significant lead with existing products on the market [8] Competitive Landscape - Eli Lilly is currently the leader in the weight management market with its product Zepbound, which has seen exceptional sales growth [8][11] - Eli Lilly has several promising candidates in its pipeline, including orforglipron and retatrutide, which are expected to enhance its competitive position [9][10][11] - Despite Pfizer's efforts, Eli Lilly's established presence and upcoming product launches may allow it to maintain its leadership in the anti-obesity market for the foreseeable future [11] Financial Outlook - Pfizer's recent financial performance has been underwhelming, with concerns about the impending patent cliff for its top growth driver, Eliquis [13] - However, the acquisition of Metsera and the potential success in the weight management sector could help Pfizer rebound [14] - The company also has a strong dividend program, which may attract investors despite current challenges [15]

Core Insights - Mangoceuticals, Inc. has launched two new programs, MangoRx Direct and PeachesRx Direct, providing direct access to GLP-1 medications Zepbound® and Wegovy® through a secure telemedicine platform [1][2][3] Group 1: Company Overview - Mangoceuticals focuses on health and wellness products, utilizing telemedicine to offer services under the brands MangoRx and PeachesRx [1] - The company aims to simplify and sustain weight-loss treatment, offering a medication management membership for $99 per month, which includes unlimited telehealth visits and lifestyle coaching [3] - The company is positioned to address the obesity epidemic affecting 42% of U.S. adults, which costs the healthcare system over $210 billion annually [4] Group 2: Product Offerings - The GLP-1 medications will be available through Eli Lilly's LillyDirect® and Novo Nordisk's NovoCare Pharmacy, with virtual consultations and personalized treatment plans provided [2] - Medications are priced starting at $499 per month, with options for home delivery or local pharmacy pickup, and no insurance is required [3] Group 3: Market Context - The launch aligns with the White House's initiative to reduce government pricing for GLP-1 medications to $245 per month and offer $50 copays for Medicare patients with obesity starting mid-2026 [3] - The company believes it can serve millions of individuals seeking effective and affordable weight management solutions [4]

Core Insights - WW International, Inc. has announced a collaboration with Amazon Pharmacy to enhance access to weight management medications for WeightWatchers Clinic members [1][5] - The partnership aims to simplify the process of obtaining medications, providing real-time availability, automatic savings, and reliable home delivery [2][3] Collaboration Details - WeightWatchers Clinic members can now check medication availability, compare delivery times, and utilize Amazon Pharmacy for prescriptions, improving convenience [2][4] - Amazon Pharmacy will automatically apply manufacturer-sponsored savings at checkout, eliminating the need for manual coupon entry [3][4] Service Enhancements - The collaboration leverages Amazon's logistics for fast and reliable delivery, including free two-day shipping for Prime members and same-day delivery in eligible areas [3][4] - WeightWatchers emphasizes a holistic approach, combining medication access with nutrition programs and community support to enhance member outcomes [6] Performance Metrics - A recent study indicated that WeightWatchers Clinic members lost an average of 21% of their body weight over 12 months, surpassing results from other telehealth providers and clinical trials [6] Company Background - WeightWatchers is recognized as a leader in science-backed weight management, with over 60 years of experience and a comprehensive support system [7] - The company offers a personalized approach that includes clinical interventions and a global network of coaches, aiming to provide sustainable health outcomes for its members [7]

Core Viewpoint - Eli Lilly's recent setbacks in the oral GLP-1 market present a potential buying opportunity despite a decline in share price [1][8][14] Company Analysis - Eli Lilly has faced challenges with its investigational oral GLP-1 candidate, orforglipron, which did not meet market expectations in a phase 3 study for weight management, leading to a significant drop in share price [1][8] - The company remains a leader in the GLP-1 market, with its product Zepbound generating billions in quarterly sales, primarily competing with Novo Nordisk's Wegovy [4][12] - Despite the recent setback, Eli Lilly's financial results are strong, and it has a robust pipeline with potential blockbusters in oncology and immunology [14] Industry Analysis - The oral GLP-1 market is projected to reach $20 billion by 2030, with a significant portion potentially coming from weight management sales due to the growing popularity of anti-obesity medicines [6][7] - Currently, there is only one oral GLP-1 drug approved by the FDA, Rybelsus, which generated $3.6 billion in sales last year, indicating a large untapped market for oral alternatives [6][5] - Novo Nordisk stands to benefit from Eli Lilly's setbacks, as it has initiated phase 3 studies for its investigational weight loss medicine, amycretin, which could outperform orforglipron [12][13]

Core Viewpoint - Eli Lilly has shown significant clinical progress and financial results, positioning itself as the largest healthcare player globally, with a market cap of approximately $684 billion as of August 1, and has the potential to reach a $2 trillion valuation within seven years [1]. Group 1: Weight Management Market - The weight management medicines market is rapidly growing, projected to reach $150 billion in sales by 2035, up from $15 billion last year [2]. - Eli Lilly's weight loss therapy, Zepbound, has proven to be highly effective, outperforming its main competitor, Novo Nordisk's Wegovy, in clinical trials, contributing to substantial revenue growth for the company [3][10]. - Eli Lilly is addressing the limitations of Zepbound, such as its weekly injection requirement, by developing orforglipron, an oral GLP-1 medicine, which has shown promising weight loss results in diabetes patients [6][5]. Group 2: Pipeline and Product Diversification - Eli Lilly's pipeline includes innovative products like bimagrumab, which can mitigate muscle loss associated with weight loss therapies, showing significant weight reduction in combination with Wegovy [8]. - The company is also developing retatrutide, which mimics the action of three gut hormones, potentially making it more effective than Zepbound if approved [9]. - Beyond weight management, Eli Lilly has a strong portfolio in diabetes, oncology, and immunology, with products like Mounjaro, Verzenio, and Ebglyss, indicating a diversified and robust pipeline [11][12]. Group 3: Valuation and Market Outlook - Eli Lilly's forward price-to-earnings ratio is around 37, which is high compared to the healthcare industry's average of 16.5, but justified by its rapid sales and profit growth, along with a strong pipeline and dividend program [13]. - The company is expected to outperform the market and achieve the necessary growth to reach a $2 trillion valuation by the end of 2032 [13].